An example of this is described in a recent study of patients with coronavirus disease 2019 (COVID-19) (34), in whom complement activation products from the classical (C4d), the alternative (C3bBbP), the common (C3bc), and the terminal pathway (C5a and sC5b-9) were measured. The gene discussed is C5; the disease is glycogen storage disease VI.